Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman Sells 60,000 Shares

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 60,000 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the completion of the sale, the director now directly owns 501,233 shares in the company, valued at approximately $25,643,080.28. This represents a 10.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

William Hoffman also recently made the following trade(s):

• On Tuesday, October 29th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $50.05, for a total transaction of $2,002,000.00.
• On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00.
• On Monday, September 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.83, for a total value of $1,833,200.00.

Inari Medical Trading Down 3.9 %

Shares of NARI opened at $49.00 on Thursday. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $67.13. The business’s fifty day moving average is $45.52 and its 200 day moving average is $47.19.

Institutional Investors Weigh In On Inari Medical

Several hedge funds and other institutional investors have recently made changes to their positions in NARI. Vanguard Group Inc. boosted its position in shares of Inari Medical by 11.1% during the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after buying an additional 561,562 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock worth $65,021,000 after acquiring an additional 610,468 shares in the last quarter. Vestal Point Capital LP boosted its holdings in Inari Medical by 342.9% during the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after purchasing an additional 1,200,000 shares during the last quarter. Point72 Asset Management L.P. grew its position in Inari Medical by 113.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock worth $71,324,000 after purchasing an additional 786,691 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in Inari Medical by 353.1% in the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock valued at $48,595,000 after buying an additional 786,501 shares during the last quarter. 90.98% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NARI has been the topic of several research analyst reports. Leerink Partners began coverage on Inari Medical in a research report on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 target price on the stock. Canaccord Genuity Group increased their price target on Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Truist Financial lifted their price objective on shares of Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a research note on Tuesday, October 29th. Leerink Partnrs upgraded shares of Inari Medical to a “hold” rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.